Clinical risks of St John’s Wort (Hypericum perforatum) co-administration

References

• Bahramsoltani R, Farzaei MH, Farahani MS, et al. Phytochemical constituents as future antidepressants: a comprehensive review. Rev Neurosci. 2015;26(6):699–719.
   PubMed Web of Science ®Google Scholar
• Farahani MS, Bahramsoltani R, Farzaei MH, et al. Plant-derived natural medicines for the management of depression: an overview of mechanisms of action. Rev Neurosci. 2015;26(3):305–321.
   PubMed Web of Science ®Google Scholar
• Saddiqe Z, Naeem I, Maimoona A. A review of the antibacterial activity of Hypericum perforatum L. J Ethnopharmacol. 2010;131(3):511–521.
   PubMed Web of Science ®Google Scholar
• Öztürk N, Korkmaz S, Öztürk Y. Wound-healing activity of St. John’s wort (Hypericum perforatum L.) on chicken embryonic fibroblasts. J Ethnopharmacol. 2007;111(1):33–39.
   PubMed Web of Science ®Google Scholar
• Husain GM, Chatterjee SS, Singh PN, et al. Hypolipidemic and antiobesity-like activity of standardised extract of Hypericum perforatum L. in rats. ISRN Pharmacol. 2011;2011:505247.
   PubMedGoogle Scholar
• Dost T, Ozkayran H, Gokalp F, et al. The effect of Hypericum perforatum (St. John’s Wort) on experimental colitis in rat. Dig Dis Sci. 2009;54(6):1214–1221.
   PubMed Web of Science ®Google Scholar
• Feily A, Abbasi N. The inhibitory effect of Hypericum perforatum extract on morphine withdrawal syndrome in rat and comparison with clonidine. Phytother Res. 2009;23(11):1549–1552.
   PubMed Web of Science ®Google Scholar
• Davids LM, Kleemann B, Kacerovská D, et al. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B. 2008;91(2):67–76.
   PubMed Web of Science ®Google Scholar
• Zou YP, Lu YH, Wei DZ. Protective effects of a flavonoid-rich extract of Hypericum perforatum L. against hydrogen peroxide-induced apoptosis in PC12 cells. Phytother Res. 2010;24(S1):S6–S10.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Pan S-Q, et al. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol. 2004;18(2):262–276.
   PubMed Web of Science ®Google Scholar
• Bhadra R, Ravakhah K, Ghosh RK. Herb-drug interaction: the importance of communicating with primary care physicians. Australas Med J. 2015;8(10):315–319.
   PubMed Web of Science ®Google Scholar
• Mannel M. Drug interactions with St John’s wort. Drug Safety. 2004;27(11):773–797.
   PubMed Web of Science ®Google Scholar
• Borrelli F, Izzo AA. Herb–drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. Aaps J. 2009;11(4):710–727.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290(11):1500–1504.
   PubMed Web of Science ®Google Scholar
• Liu J, Sridhar J, Foroozesh M. Cytochrome P450 family 1 inhibitors and structure-activity relationships. Molecules. 2013;18(12):14470–14495.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–396.
   PubMed Web of Science ®Google Scholar
• Srivalli KMR, Lakshmi P. Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharmaceut Sci. 2012;48(3):353–367.
   Web of Science ®Google Scholar
• Glaeser H. Importance of P-glycoprotein for drug–drug interactions. In: Drug transporters, volume 201 of the series handbook of experimental pharmacology. Springer; 2011. p. 285–297.
   Google Scholar
• Hennessy M, Kelleher D, Spiers J, et al. St John’s wort increases expression of P‐glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002;53(1):75–82.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Abdollahi M. An update on the ability of St. John’s wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012;8(6):691–708.
   PubMed Web of Science ®Google Scholar
• Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci. 2000;97(13):7500–7502.
   PubMed Web of Science ®Google Scholar
• Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John’s wort drug interactions. Curr Drug Metab. 2008;9(10):1027–1037.
   PubMed Web of Science ®Google Scholar
• Dalmizrak O, Kulaksiz-Erkmen G, Ozer N. Evaluation of the in vitro inhibitory impact of hypericin on placental glutathione S-transferase pi. Protein J. 2012;31(7):544–549.
   PubMed Web of Science ®Google Scholar
• Johne A, Schmider J, Brockmöller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol. 2002;22(1):46–54.
   PubMed Web of Science ®Google Scholar
• Lei H-P, Yu X-Y, Xie H-T, et al. Effect of St. John’s wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. Xenobiotica. 2010;40(4):275–281.
   PubMed Web of Science ®Google Scholar
• Andren L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007;63(10):913–916.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70(6):518–524.
   PubMed Web of Science ®Google Scholar
• Eggertsen R, Andreasson Å, Andrén L. Effects of treatment with a commercially available St John’s wort product (Movina®) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand J Prim Health Care. 2007;25(3):154–159.
   PubMed Web of Science ®Google Scholar
• Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John’s wort. Am J Med. 2009;122(2):e1–e2.
   PubMed Web of Science ®Google Scholar
• Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000;68(6):605–612.
   PubMed Web of Science ®Google Scholar
• Trana C, Toth G, Wijns W, et al. St. John’s wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John’s Trial). J Cardiovasc Transl Res. 2013;6(3):411–414.
   PubMed Web of Science ®Google Scholar
• Lau WC, Welch TD, Shields T, et al. The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011;57(1):86–93.
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;57(5):592–599.
   PubMed Web of Science ®Google Scholar
• Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol. 2006;46(11):1370–1378.
   PubMed Web of Science ®Google Scholar
• Van Strater AC, Bogers JP. Interaction of St John’s wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol. 2012;27(2):121–124.
   PubMed Web of Science ®Google Scholar
• Turton-Weeks SM, Barone GW, Gurley BJ, et al. St John’s wort: a hidden risk for transplant patients. Prog Transplant. 2001;11(2):116–120.
   PubMedGoogle Scholar
• Karliova M, Treichel U, Malagò M, et al. Interaction of Hypericum perforatum (St. John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000;33(5):853–855.
   PubMed Web of Science ®Google Scholar
• Mai I, Krüger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther. 2000;38(10):500–502.
   PubMed Web of Science ®Google Scholar
• Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John’s wort-cyclosporine drug interaction. Clin Pharmacol Ther. 2004;76(4):330–340.
   PubMed Web of Science ®Google Scholar
• Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother. 2000;34(9):1013–1016.
   PubMed Web of Science ®Google Scholar
• Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John’s wort) after organ transplantation. Am J Kidney Dis. 2001;38(5):1105–1107.
   PubMed Web of Science ®Google Scholar
• Bauer S, Störmer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol. 2003;55(2):203–211.
   PubMed Web of Science ®Google Scholar
• Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John’s wort with cyclosporine. Transpl Int. 2003;16(7):543–544.
   PubMed Web of Science ®Google Scholar
• Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet. 2000;355(9203):548–549.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Park JM, Chen YL, et al. Effects of St. John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2004;44(1):89–94.
   PubMed Web of Science ®Google Scholar
• Mai I, Stormer E, Bauer S, et al. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant. 2003;18(4):819–822.
   PubMed Web of Science ®Google Scholar
• Hall SD, Wang Z, Huang SM, et al. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74(6):525–535.
   PubMed Web of Science ®Google Scholar
• Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St. John’s Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71(6):402–408.
   PubMed Web of Science ®Google Scholar
• Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003;56(6):683–690.
   PubMed Web of Science ®Google Scholar
• Fogle RH, Murphy PA, Westhoff CL, et al. Does St. John’s wort interfere with the antiandrogenic effect of oral contraceptive pills? Contraception. 2006;74(3):245–248.
   PubMed Web of Science ®Google Scholar
• Will-Shahab L, Bauer S, Kunter U, et al. St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol. 2009;65(3):287–294.
   PubMed Web of Science ®Google Scholar
• Hojo Y, Echizenya M, Ohkubo T, et al. Drug interaction between St John’s wort and zolpidem in healthy subjects. J Clin Pharm Ther. 2011;36(6):711–715.
   PubMed Web of Science ®Google Scholar
• Kawaguchi A, Ohmori M, Tsuruoka S, et al. Drug interaction between St John’s wort and quazepam. Br J Clin Pharmacol. 2004;58(4):403–410.
   PubMed Web of Science ®Google Scholar
• Bell EC, Ravis WR, Lloyd KB, et al. Effects of St. John’s wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother. 2007;41(2):229–234.
   PubMed Web of Science ®Google Scholar
• Smith PF, Bullock JM, Booker BM, et al. Induction of imatinib metabolism by Hypericum perforatum. Blood. 2004;104(4):1229–1230.
   PubMed Web of Science ®Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76(4):323–329.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94(16):1247–1249.
   PubMed Web of Science ®Google Scholar
• Goey AK, Meijerman I, Rosing H, et al. The effect of St John’s wort on the pharmacokinetics of docetaxel. Clin Pharmacokinet. 2014;53(1):103–110.
   PubMed Web of Science ®Google Scholar
• Mueller SC, Uehleke B, Woehling H, et al. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75(6):546–557.
   PubMed Web of Science ®Google Scholar
• Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66(4):338–345.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52(7):772–779.
   PubMed Web of Science ®Google Scholar
• Portoles A, Terleira A, Calvo A, et al. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol. 2006;46(10):1188–1194.
   PubMed Web of Science ®Google Scholar
• Wang XD, Li JL, Lu Y, et al. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical herb-drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852(1–2):534–544.
   PubMed Web of Science ®Google Scholar
• Schwarz U, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther. 2007;81(5):669–678.
   PubMed Web of Science ®Google Scholar
• Tannergren C, Engman H, Knutson L, et al. St John’s wort decreases the bioavailability of R-and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther. 2004;75(4):298–309.
   PubMed Web of Science ®Google Scholar
• Lundahl A, Hedeland M, Bondesson U, et al. The effect of St. John’s wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci. 2009;36(4):433–443.
   PubMed Web of Science ®Google Scholar
• Wang LS, Zhou G, Zhu B, et al. St John’s wort induces both cytochrome P450 3A4–catalyzed sulfoxidation and 2C19–dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191–197.
   PubMed Web of Science ®Google Scholar
• Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol. 2004;44(1):95–101.
   PubMed Web of Science ®Google Scholar
• Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St. John’s wort and theophylline. Ann Pharmacother. 1999;33(4):502.
   PubMed Web of Science ®Google Scholar
• Stage TB, Pedersen RS, Damkier P, et al. Intake of St John’s wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. Br J Clin Pharmacol. 2015;79(2):298–306.
   PubMed Web of Science ®Google Scholar
• Bell EC, Ravis WR, Chan HM, et al. Lack of pharmacokinetic interaction between St. John’s wort and prednisone. Ann Pharmacother. 2007;41(11):1819–1824.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet. 2000;355(9203):547–548.
   PubMed Web of Science ®Google Scholar
• de Maat MM, Hoetelmans RM, Math t RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS. 2001;15(3):420–421.
   PubMed Web of Science ®Google Scholar
• Jackson A, D’Avolio A, Moyle G, et al. Pharmacokinetics of the co-administration of boceprevir and St John’s wort to male and female healthy volunteers. J Antimicrob Chemother. 2014;69(7):1911–1915.
   PubMed Web of Science ®Google Scholar
• Nieminen TH, Hagelberg NM, Saari TI, et al. St John’s wort greatly reduces the concentrations of oral oxycodone. Eur J Pain. 2010;14(8):854–859.
   PubMed Web of Science ®Google Scholar
• Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short‐term and long‐term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005;78(1):25–33.
   PubMed Web of Science ®Google Scholar
• Markert C, Ngui P, Hellwig R, et al. Influence of St. John’s wort on the steady-state pharmacokinetics and metabolism of bosentan. Int J Clin Pharmacol Ther. 2014;52(4):328–336.
   PubMed Web of Science ®Google Scholar
• Markert C, Kastner IM, Hellwig R, et al. The effect of induction of CYP3A4 by St John’s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic Clin Pharmacol Toxicol. 2015;116(5):423–428.
   PubMed Web of Science ®Google Scholar
• Haritos V, Ghabrial H, Ahokas J, et al. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E-and Z-doxepin. Pharmacogenetics. 2000;10(7):591–603.
   PubMedGoogle Scholar
• Wu Z-L, Huang S-L, Ou-Yang D-S, et al. Clomipramine N-demethylation metabolism in human liver microsomes. Zhongguo Yao Li Xue Bao= Acta Pharmacologica Sinica. 1998;19(5):433–436.
   PubMed Web of Science ®Google Scholar
• Madden GJ, Kalman D. Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking. Nicotine Tob Res. 2010;12(4):416–422.
   PubMed Web of Science ®Google Scholar
• Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61(6):889–892.
   PubMedGoogle Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 suppl 1):III-39–III-43.
   Web of Science ®Google Scholar
• Sigaroudi A, Kullak-Ublick GA, Weiler S. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. Eur J Clin Pharmacol. 2016;72(3):377–378.
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126–142.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishiya Y, Kurihara A, et al. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23(6):412–420.
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(7):1096–1104.
   PubMed Web of Science ®Google Scholar
• Ko JW, Desta Z, Soukhova NV, et al. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol. 2000;49(4):343–351.
   PubMed Web of Science ®Google Scholar
• McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost. 2015;41(3):300–314.
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Shapiro NL, Ibrahim S, et al. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5(3):433–451.
   PubMed Web of Science ®Google Scholar
• Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3(3):221–230.
   PubMedGoogle Scholar
• Söderberg MM, Dahl M-L. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013;14(11):1319–1336.
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410–418.
   PubMed Web of Science ®Google Scholar
• Bakken GV, Rudberg I, Christensen H, et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37(2):254–258.
   PubMed Web of Science ®Google Scholar
• Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23(3):229–232.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther. 2004;75(5):422–433.
   PubMed Web of Science ®Google Scholar
• Hom J, Hansten P. St. John’s wort interactions: what’s new? Pharm Times. 2004;70(5):64–66.
   Google Scholar
• Kuhn B, Jacobsen W, Christians U, et al. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4. J Med Chem. 2001;44(12):2027–2034.
   PubMed Web of Science ®Google Scholar
• Dabrowska-Zamojcin E, Pawlik A, Domański L, et al. Cyclosporine and sirolimus interaction in a kidney transplant patient. Transplant Proc. 2005;37(5):2317–2319.
   PubMed Web of Science ®Google Scholar
• Cristóbal GH, Martínez CV, García DLPA, et al. Decreased everolimus blood concentration associated with consumption of St. John’s wort (Hypericum perforatum) extract sweets. Farm Hosp. 2017;41(4):565–566.
   PubMedGoogle Scholar
• Lake B, Ball S, Kao J, et al. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002;32(10):835–847.
   PubMed Web of Science ®Google Scholar
• Brielmaier BD. Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent. Proc (Bayl Univ Med Cent. 2006;19(1):54–59.
   PubMedGoogle Scholar
• Mizuno K, Katoh M, Okumura H, et al. Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos. 2009;37(2):345–351.
   PubMed Web of Science ®Google Scholar
• Qi JW, Nakamura K, Hosokawa S, et al. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John’s wort. Biol Pharm Bull. 2005;28(8):1467–1471.
   PubMed Web of Science ®Google Scholar
• Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981;6(4):245–258.
   PubMed Web of Science ®Google Scholar
• Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab. 2003;4(4):319–329.
   PubMed Web of Science ®Google Scholar
• Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol. 2007;61(3):222–229.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang F, Li Q, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245–249.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ariyoshi N, Iwatsubo T, et al. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005;28(5):882–885.
   PubMed Web of Science ®Google Scholar
• Zhao P, Lee CA, Kunze KL. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos. 2007;35(5):704–712.
   PubMed Web of Science ®Google Scholar
• Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci. 2001;4(2):185–200.
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. J Pharm Sci. 2005;94(2):397–408.
   PubMed Web of Science ®Google Scholar
• Ishida K, Taira S, Morishita H, et al. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull. 2008;31(6):1297–1300.
   PubMed Web of Science ®Google Scholar
• Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5α reductase. Rev Urol. 2005;7(4):203–210.
   PubMedGoogle Scholar
• Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317–326.
   PubMed Web of Science ®Google Scholar
• Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197(2):189–204.
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Goa KL. Lopinavir/ritonavir. Drugs. 2003;63(8):769–802.
   PubMed Web of Science ®Google Scholar
• Eagling V, Wiltshire H, Whitcombe I, et al. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica. 2002;32(1):1–17.
   PubMed Web of Science ®Google Scholar
• Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32(12):1462–1467.
   PubMed Web of Science ®Google Scholar
• Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012;40(4):803–814.
   PubMed Web of Science ®Google Scholar
• Ogburn ET, Jones DR, Masters AR, et al. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos. 2010;38(7):1218–1229.
   PubMed Web of Science ®Google Scholar
• Garg V, Kauffman RS, Beaumont M, et al. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17(7):1211–1221.
   PubMed Web of Science ®Google Scholar
• Rangnekar AS, Fontana RJ. Managing drug-drug interactions with boceprevir and telaprevir. Clin Liver Disease. 2012;1(2):36–40.
   Google Scholar
• Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257–265.
   PubMed Web of Science ®Google Scholar
• Peng C-C, Shi W, Lutz JD, et al. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug Metab Dispos. 2012;40(3):426–435.
   PubMed Web of Science ®Google Scholar
• Brüggemann RJ, Alffenaar J-WC, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–1458.
   PubMed Web of Science ®Google Scholar
• Erve JC, Gauby S, Maynard JW Jr, et al. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Chem Res Toxicol. 2013;26(6):926–936.
   PubMed Web of Science ®Google Scholar
• Sidharta P, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet. 2015;54(5):457–471.
   PubMed Web of Science ®Google Scholar
• Hattesohl M, Feistel B, Sievers H, et al. Extracts of Valeriana officinalis L. sl show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine. 2008;15(1):2–15.
   PubMed Web of Science ®Google Scholar
• Fiebich BL, Knörle R, Appel K, et al. Pharmacological studies in an herbal drug combination of St. John’s Wort (Hypericum perforatum) and passion flower (Passiflora incarnata): in vitro and in vivo evidence of synergy between Hypericum and Passiflora in antidepressant pharmacological models. Fitoterapia. 2011;82(3):474–480.
   PubMed Web of Science ®Google Scholar
• Basti AA, Moshiri E, Noorbala -A-A, et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439–442.
   PubMed Web of Science ®Google Scholar